Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: A meta-analysis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zhang, Lijuan ^a   Jiang, Nan ^a   Shi, Yuexian ^a   Li, Shipeng ^a   Wang, Peiguo ^a   Zhao, Yue ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVERSE EFFECTS; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); FEMALE; HEAD AND NECK NEOPLASMS; HUMAN; INDUCTION CHEMOTHERAPY; MALE; META ANALYSIS; MORTALITY; ODDS RATIO; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PUBLISHING; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CLINICAL TRIALS AS TOPIC; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INDUCTION CHEMOTHERAPY; MALE; NEOPLASM STAGING; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PUBLICATION BIAS; TREATMENT OUTCOME;

EID: 84930650016     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10798     Document Type: Article

References (42)

1. Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA Cancer J Clin 55, 74-108 (2005).
2. Argiris, A., Karamouzis, M. V., Raben, D. & Ferris, R. L. Head and neck cancer. Lancet 371, 1695-1709 (2008).
3. Spector, J. G. et al. Management of stage II (T2N0M0) glottic carcinoma by radiotherapy and conservation surgery. Head Neck 21, 116-123 (1999).
4. Spector, J. G. et al. Stage I (T1 N0 M0) squamous cell carcinoma of the laryngeal glottis: therapeutic results and voice preservation. Head Neck 21, 707-717 (1999).
5. Sessions, D. G., Lenox, J., Spector, G. J., Chao, C. & Chaudry, O. A. Analysis of treatment results for base of tongue cancer. Laryngoscope 113, 1252-1261 (2003).
6. Sessions, D. G., Lenox, J. & Spector, G. J. Supraglottic laryngeal cancer: analysis of treatment results. Laryngoscope 115, 1402-1410 (2005).
7. Seiwert, T. Y. & Cohen, E. E. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 92, 1341-1348 (2005).
8. Posner, M. R. et al. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol 31, 778-785 (2004).
9. Lefebvre, J. L. et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88, 890-899 (1996).
10. Forastiere, A. A. Head and neck cancer: overview of recent developments and future directions. Semin Oncol 27, 1-4 (2000).
11. Adelstein, D. J. et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21, 92-98 (2003).
12. Brizel, D. M. et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338, 1798-1804 (1998).
13. Budach, V. et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 23, 1125-1135 (2005).
14. Pignon, J. P., le Maitre, A., Maillard, E. & Bourhis, J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92, 4-14 (2009).
15. Forastiere, A. A. et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349, 2091-2098 (2003).
16. Ang, K. K. et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol 23, 3008-3015 (2005).
17. Argiris, A. Induction chemotherapy for head and neck cancer: will history repeat itself? J Natl Compr Canc Netw 3, 393-403 (2005).
18. Paccagnella, A. et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 21, 1515-1522 (2010).
19. Chen, J. W. et al. A randomized control trial of induction chemotherapy combined with concurrent chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma. Journal of Chongqing Medical University 36, 1103-1106 (2011).
20. Haddad, R. et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14, 257-264 (2013).
21. Cohen, E. E. et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 32, 2735-2743 (2014).
22. Hitt, R. et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 25, 216-225 (2014).
23. Ghi, M. G. et al. Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/ Cisplatin/5-Fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III factorial study (NCT01086826). J Clin Oncol 32 (2014).
24. Gregoire, V., Lefebvre, J. L., Licitra, L. & Felip, E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl 5), v184-v186 (2010).
25. Sher, D. J. et al. Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. Int J Radiat Oncol Biol Phys 81, e813-e818 (2011).
26. Brizel, D. M. & Vokes, E. E. Induction chemotherapy: to use or not to use? That is the question. Semin Radiat Oncol 19, 11-16 (2009).
27. Pignon, J. P., Bourhis, J., Domenge, C. & Designe, L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355, 949-955 (2000).
28. Posner, M. R. et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357, 1705-1715 (2007).
29. Vermorken, J. B. et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357, 1695-1704 (2007).
30. Pointreau, Y. et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101, 498-506 (2009).
31. Ma, J. et al. Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis. Oral Oncol 48, 1076-1084 (2012).
32. Su, Y. X., Zheng, J. W., Zheng, G. S., Liao, G. Q. & Zhang, Z. Y. Neoadjuvant chemotherapy of cisplatin and fluorouracil regimen in head and neck squamous cell carcinoma: a meta-analysis. Chin Med J (Engl) 121, 1939-1944 (2008).
33. Hitt, R. et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23, 8636-8645 (2005).
34. Rooney, M. et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 55, 1123-1128 (1985).
35. Aapro, M. S. et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47, 8-32 (2011).
36. Sugimoto, C. et al. Granulocyte colony-stimulating factor (G-CSF)-mediated signaling regulates type IV collagenase activity in head and neck cancer cells. Int J Cancer 93, 42-46 (2001).
37. Li, X. et al. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials. Ann Oncol 25, 455-461 (2014).
38. Rades, D. et al. Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). Strahlenther Onkol 187, 626-632 (2011).
39. Rades, D. et al. Impact of the HPV-positivity definition on the prognostic value of HPV status in patients with locally advanced squamous cell carcinoma of the head and neck. Strahlenther Onkol 189, 856-860 (2013).
40. Linot, B., Augereau, P., Breheret, R., Laccourreye, L. & Capitain, O. Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study. Support Care Cancer 22, 2831-2837 (2014).
41. Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S. & Sydes, M. R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8, 16 (2007).
42. Mantel, N. & Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22, 719-748 (1959).